| top | |
        NEWSLETTER
|
|
Volume 6, Supplement 3 - June 2007 |
|
|
|
|
|
Contents |
|
|
|
|
| Special Issue: 43rd ASCO Annual Meeting, June 1-5, 2007 | |
| Early Detection | |
| Diagnosis & Evaluation | |
| Epidemiology & Risk Factors | |
| Etiology & Pathogenesis | |
| Integrative Medicine | |
| Overall Management | |
| Prevention | |
| Prognosis & Outcome | |
| Psychosocial Aspects | |
| Treatment | |
|
|
|
|
|
|
|
|
|
|
T. S. Armstrong, T. Mendoza, I. Gning, M. L. Smith, M. R. Gilbert, J.
Weinberg, C. Cleeland The utility of the MDASI-BT in assessing symptoms in patients with brain metastases. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2052 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P. M. Kiewe, S. Maza, D. Munz, A. Korfel, E. Thiel F-18-labeled fluorodeoxyglucose positron emission tomography for evaluation of disease extent, response to treatment and follow-up in primary CNS lymphoma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2015 |
|
|
|
|
|
A. Desjardins, D. P. Barboriak, J. E. Herndon, D. A. Reardon, J. A.
Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, H. S. Friedman, J. J.
Vredenburgh Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2029 |
|
|
|
|
|
* |
M. P. Mehta, A. Dagnault, P. Chabot, J. Suh, E. Chang, M. Fortin, R.
Timmerman, J. Grecula, L. Eubank, M. F. Renschler Identification of occult brain metastases amenable to stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment planning MRI: Results of a phase II trial of MGd and whole brain radiotherapy (WBRT) with stereotactic radiosurgery (SRS). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2037 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S. Puget, A. Valent, I. Bieche, P. Dessen, A. Kauffmann, M. Peyre, C. Dirven, C. Sainte-Rose, G. Vassal, J. Grill Identification of novel candidate genes for ependymoma progression in chromosomal regions over-represented at recurrence and detected by CGH array. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A. Narayana, S. Chheang, E. Knopp, N. Peccerelli, J. Babb, G. Johnson,
M. Gruber, J. Allen, D. Zagzag, M. Law Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2030 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
M. Bredel, H. Phillips, G. R. Harsh, K. Aldape, B. I. Sikic A regulatory network of canonical nuclear factor-κB activation predicts high-grade glioma outcome. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2007 |
|
|
|
|
|
R. Jakacki, P. Burger, T. Zhou, E. Holmes, R. Packer, J. Goldwein, M. Mehta, I. Pollack Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2017 |
|
|
|
|
|
** |
J. N. Rich, M. L. Affronti, J. M. Day, J. E. Herndon, J. A. Quinn, D. A.
Reardon, J. J. Vredenburgh, A. Desjardins, H. S. Friedman Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2070 |
|
R. P. Sanders, A. Onar, J. M. Boyett, A. Broniscer, M. Fouladi, F. A. Boop, R. A. Sanford, L. E. Kun, T. M. Merchant, A. Gajjar M1 medulloblastoma should be considered high risk at any age. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2016 |
|
|
** |
H. Yoon, A. F. Hottinger, L. M. DeAngelis, A. B. Lassman, L. E. Abrey Clinical outcome of glioblastoma multiforme patients with long-term survival. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2069 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
** |
M. L. Affronti, J. M. Day, J. E. Herndon, J. N. Rich, J. A. Quinn, D. A.
Reardon, J. J. Vredenburgh, A. Desjardins, R. E. McLendon, H. S. Friedman Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2068 |
|
L. Angelov, N. D. Doolittle, T. Siegal, D. F. Kraemer, D. Peereboom, K.
Jahnke, S. Ference, G. Barnett, J. McGregor, E. A. Neuwelt, on behalf of The
Blood Brain Barrier Disruption (BBBD) Consortium Blood brain barrier disruption (BBBD) and intra-arterial methotrexate based therapy for newly diagnosed primary CNS lymphoma: The BBBD Consortium Experience. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2014 |
|
|
T. Aoki, K. Nojima, T. Mizutani, M. Ishikawa, A. Takasu, N. Hashimoto Phase II study of ifosfamide, carboplatin and etoposide (ICE) in recurrent glioblastoma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2066 |
|
|
|
|
|
T. Batchelor, A. G. Sorensen, M. Ancukiewicz, D. G. Duda, D. N. Louis,
S. R. Plotkin, P. Ivy, P. Y. Wen, J. S. Loeffler, R. Jain A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2001 |
|
|
|
|
|
U. Bode, S. Buchen, M. Warmuth-Metz, T. Pietsch, F. Bach, G. Fleischhack Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2006 |
|
|
|
|
|
U. Bogdahn, A. Mahapatra, V. E. Olyushin, C. Mouli, V. E. Parfenov, G.
Stockhammer, S. Ludwig, G. Wuerth, H. Heinrichs, K. Schlingensiepen A phase IIb actively controlled study with the TGF-beta-2 inhibitor AP 12009 for recurrent or refractory anaplastic astrocytoma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2025 |
|
|
|
|
|
F. Bokstein, F. Kovner, Z. Ram, H. Templehoff, A. A. Kanner, D. T.
Blumenthal, B. Corn
A common sense approach to radiation treatment planning of temporal lobe GBM. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2044 |
|
|
* |
D. A. Bota, A. Desjardins, J. A. Quinn, J. N. Rich, J. J. Vredenburgh,
S. Sathornsumetee, K. Goli, A. Salvado, H. S. Friedman, D. A. Reardon
Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2053 |
|
A. A. Brandes, R. Stupp, P. Hau, S. Sleijfer, D. Lacombe, T. Gorlia, H. Yun, A.
Tosoni, R. Mirimanoff, M. J. van den Bent
EORTC Study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma--Results of a phase I trial. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2026 |
|
|
|
|
|
L. W. Buie, C. Lindley, T. Shih, M. Ewend, J. K. Smith, M. Skelton, L.
Kwock, D. Morris, C. Tucker, F. Collichio
Plasma pharmacokinetics and cerebrospinal fluid concentrations of erlotinib in high-grade gliomas: A novel, phase I, dose escalation study. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2054 |
|
|
C. A. Conrad, E. Maher, T. Cloughesy, M. Groves, M. Gilbert, T. Madden,
V. Levin, W. Priebe, C. Meyer, W. Yung
Final results of a phase I trial with the novel anthracycline derivative RTA 744 in patients with primary brain tumors. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2062 |
|
|
G. R. D'Agostino, M. Balducci, C. Anile, S. Manfrida, G. Di Lella, A.
Fiorentino, G. Mantini, G. Apicella, A. Pompucci, N. Cellini An analysis of two different schedules of radiochemotherapy with concomitant temozolomide in high grade gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2035 |
|
|
|
|
|
J. F. De Groot, M. R. Gilbert, K. R. Hess, T. Hanna, M. Groves, C.
Conrad, K. Aldape, H. Colman, V. Puduvalli, W. A. Yung
Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2024 |
|
|
A. Dicker, M. Werner-Wasik, M. Machtay, G. Mallon, M. Ramirez, D.
Andrews, W. J. Curran
A phase I trial using the proteasome inhibitor bortezomib and concurrent temazolomide and radiotherapy for high grade gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2061 |
|
|
|
|
|
* |
M. de Wit, V. Lange-Brock, A. Kruell, C. Bokemeyer
Leptomeningeal metastases: Results of different therapeutic approaches. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2047 |
|
* |
G. Dresemann, C. Hosius, Z. Nikolova, L. Letvak
Single center phase II trial analysing the role of imatinib/hydroxyurea in patients (pts) with pretreated non-progressive glioblastoma (GBM) as maintenance treatment. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2055 |
|
M. Ekenel, F. M. Iwamoto, L. S. Ben Porat, K. S. Panageas, J. Yahalom,
L. M. DeAngelis, L. E. Abrey What is the role of whole brain radiation therapy (WBRT) and high-dose cytarabine (Ara-C) as consolidation treatment after initial chemotherapy for primary CNS lymphoma (PCNSL)? 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2013 |
|
|
|
|
|
* |
A. F. Ferreira Filho, S. Saueressig, D. L. da Silva, M. P. dos Santos,
A. P. Wunder, R. Santana, C. Zetler Clinical, pathological and immunistochemistry characterization of primary breast cancer metastasizing to the central nervous system (CNS): Analysis of time to development of CNS metastasis. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2051 |
|
* |
J. B. Fiveash, S. M. Sawrie, B. L. Guthrie, S. A. Spencer, R. F.
Meredith, J. M. Markert, R. A. Nordal, R. M. Conry, L. B. Nabors A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2048 |
|
E. Franceschi, A. Tosoni, M. Ermani, V. Blatt, P. Amistà, G. Sotti, S.
Bartolini, D. Grosso, L. M. Pasetto, A. A. Brandes Should adult medulloblastoma patients at low risk receive adjuvant chemotherapy? Long-term results of a prospective study. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2018 |
|
|
|
|
|
B. Friday, C. Yu, L. Yang, D. Wigle, J. Sarkaria, A. Adjei
Potentiation of potentiate proteasome inhibitor-induced apoptosis in glioma cells by histone deacetylase inhibitors. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2038 |
|
|
|
|
|
E. Galanis, K. A. Jaeckle, M. J. Maurer, J. M. Reid, M. M. Ames, C.
Giannini, J. S. Hardwick, D. F. Moore, J. A. Zwiebel, J. C. Buckner N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2004 |
|
|
S. Gardner, M. Fisher, J. Belasco, P. Phillips, J. Finlay Phase I dose escalation of temozolomide with thiotepa and carboplatin with autologous hematopoietic cell reinfusion in patients with recurrent/refractory malignant brain tumors. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2060 |
|
|
|
|
|
K. J. Goli, A. Desjardins, J. E. Herndon, J. N. Rich, D. A. Reardon, J.
A. Quinn, S. Sathornsumetee, D. A. Bota, H. S. Friedman, J. J. Vredenburgh Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2001 |
|
|
|
|
|
* |
S. A. Grossman, S. Desideri, X. Ye, K. Szajna, M. Chamberlain, G.
Lesser, New Approaches to Brain Tumor Therapy (NABTT) CNSConsortium Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2012 |
|
|
|
|
S. Gururangan, C. Turner, C. F. Stewart, M. Kocak, T. Y. Poussaint, J.
M. Boyett, L. E. Kun, V. Karsten, S. L. Gerson, H. S. Friedman Phase I trial of VNP40101M in children with recurrent brain tumors--A Pediatric Brain Tumor Consortium (PBTC) study. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2059 |
|
|
H.
M. El-Shenshawy, A. Abd El-Razek, h. Bader Hypofractionated radiotherapy versus conventional fractionated radiotherapy in elderly patients with glioblastoma multiforme. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2042 |
|
|
F.
M. Iwamoto, A. M. Omuro, J. J. Raizer, C. P. Nolan, A. Hormigo, A. B.
Lassman, I. T. Gavrilovic, L. E. Abrey A phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastases. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2050 |
|
|
K. Jahnke, D. F. Kraemer, D. Fortin, S. Bell, N. D. Doolittle, K. R.
Knight, L. L. Muldoon, E. A. Neuwelt Intra-arterial chemotherapy and osmotic blood-brain barrier disruption for primitive neuroectodermal tumors. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2046 |
|
|
* |
T. Jauch, P. Hau, U. Bogdahn
Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas (HGG). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2034 |
|
|
|
|
R. Kazerooni, C. Conrad, C. Baud, M. Johansen, N. Thapar, C. Meyer, W.
Priebe, T. Madden
Phase I clinical pharmacokinetics of RTA 744: A blood brain barrier penetrating anthracycline active against high-grade glioma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2045 |
|
|
J. Kirkpatrick, A. Desjardins, J. Quinn, J. Rich, J. Vredenburgh, S.
Sathornsumetee, S. Gururangan, C. Sidor, H. Friedman, D. Reardon
Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2065 |
|
|
Y. Ko, T. Neuhaus, R. Müller, G. Grabenbauer, J. Hedde, H. Schüller,
M. Kocher, S. Stier, R. Ullrich, R. Fietkau
A phase III trial of topotecan and whole brain radiation (WBRT) therapy for patients with CNS metastases due to lung cancer. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2049 |
|
|
K. Kramer, S. Modak, B. H. Kushner, M. Souweidane, S. Wolden, J. Humm,
P. Zanzonico, P. Smith-Jones, S. Larson, N. Cheung Metastatic neuroblastoma (NB) to the central nervous system (CNS): Improved outcome with combined modality including 131-I-8H9 or 131-I-3F8 radioimmunotherapy (RIT) delivered through the cerebrospinal fluid (CSF). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2022 |
|
|
* |
G. J. Lesser, V. Stieber, D. Case, G. Enevold, R. Rosdhal, S. Tatter, T.
Ellis, K. McMullen, E. Shaw, Wake Forest University Community Clinical
OncologyProgram Research Base (WFURB)
A phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2067 |
|
|
|
|
* |
L. M. Liau, R. M. Prins, S. K. Odesa, M. Y. Yang, M. S. Lin, H.
Khan-Farooqi,
H. Soto, A. Lai, M. Bosch, A. Boynton, T. F. Cloughesy
Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2021 |
|
|
|
|
N. A. Mohile, L. E. Abrey, S. C. Lymberis, S. Karimi, B. L. Hou, P. H.
Gutin
A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2028 |
|
|
|
|
|
** |
H. Nakagawa, M. Yoshida, T. Motozaki, K. Yoshioka, K. Itoh
Clinical results of continuous intrathecal or intracavitary administration of sodium butyrate for patients with recurrent and progressive malignant glioma: Experience with 23 cases. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2040 |
|
L. B. Nabors, M. Rosenfeld, M. Chamberlain, S. Phuphanich, T. Batchelor,
J. Supko, S. Desideri, Y. Xiaobu, J. Wright, S. Grossman
A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2058 |
|
|
|
|
|
J. R. Perry, L. Rogers, N. Laperriere, J. Julian, W. Geerts, G. Agnelli,
M. Malkin, R. Sawaya, R. Baker, M. Levine, for the Ontario Clinical Oncology
Group and PRODIGE Investigators, Hamilton, Ontario, Canada PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2011 |
|
|
S. Phuphanich, M. Chamberlain, T. Mikkelsen, X. Ye, S. A. Grossman, T.
Batchelor, G. Lesser, J. D. Fisher, S. Desideri, New Approaches to Brain
Tumor Therapy (NABTT) CNSConsortium A phase I study of SDX-102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2063 |
|
|
J. A. Quinn, J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins,
S. Gururangan, A. H. Friedman, J. H. Carter, S. Threatt, H. S. Friedman
Phase II trial of Gliadel plus O6-benzylguanic (O6-BG) for patients with recurrent glioblastoma multiforme. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2036 |
|
|
|
|
|
E. Razis, P. Selviaridis, J. Fletcher, S. Labropoulos, R. Caprioli, G.
Karkavelas, M. Zhu, T. Kalebic, J. Norris, G. Fountzilas
Biochemical evidence of tumor response and measurable levels of the drug in glioblastoma tissue from patients treated with imatinib. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2023 |
|
|
|
|
|
D. Reardon, K. Fink, B. Nabors, T. Cloughesy, S. Plotkin, D. Schiff, J.
Raizer, S. Krueger, M. Picard, T. Mikkelsen Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2002 |
|
|
|
|
|
H. I. Robins, P. Y. Wen, S. M. Chang, J. Kuhn, K. Lamborn, T. Cloughesy,
M. R. Glibert, W. K. Yung, J. Dancey, M. D. Prados Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2057 |
|
|
* |
G. B. Roldán, J. Scott, D. George, J. Easaw, E. Yan, I. Parney, G.
Cairncross, P. Forsyth Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2019 |
|
|
|
|
S. Ryu, J. Rock, R. Jain, S. Ellika, J. Jin, J. Anderson Single fraction radiosurgery of epidural spinal cord compression: Tumor control and neurologic outcome. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2041 |
|
|
|
|
|
J. H. Sampson, K. D. Aldape, M. R. Gilbert, S. J. Hassenbusch, R. Sawaya,
B. Schmittling, G. E. Archer, D. Mitchell, D. D. Bigner, D. A. Reardon, A.
B. Heimberger Temozolomide as a vaccine adjuvant in GBM. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2020 |
|
|
S. Sathornsumetee, J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A.
Quinn, S. Gururangan, M. J. Egorin, A. J. Salvado, H. S. Friedman, D. A.
Reardon
Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2027 |
|
|
|
|
|
W. R. Shapiro, M. P. Mehta, C. Langer, A. Bezjak, R. Timmerman, D. Brachman, J.
Suh, J. A. Smith, S. Phan, M. F. Renschler Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2010 |
|
|
E. G. Shaw, S. A. Grossman, K. A. Carson, J. D. Fisher, L. Kleinberg,
New Approaches to Brain Tumor Therapy (NABTT) CNSConsortium Phase I study of gadolinium texaphyrin in newly diagnosed glioblastoma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2064 |
|
|
|
|
|
R. Soffietti, R. Rudà, E. Laguzzi, L. Buttolo, A. Pace, C. Carapella,
M. Riva, M. Salvati, A. Silvani, M. Caroli
Treatment of gliomatosis cerebri with temozolomide: A retrospective study of the AINO (Italian Association for Neuro-Oncology). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2033 |
|
|
* |
H. M. Strik, J. H. Buhk, H. C. Bock, M. Nitsche, A. Giese, M. Baehr Rechallenge of malignant gliomas with temozolomide --Can it be effective? 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2072 |
|
R.
Stupp, R. Goldbrunner, B. Neyns, U.
Schlegel, P. Clement, G. G. Grabenbauer, M. E. Hegi, J. Nippgen, M. Picard,
M. Weller Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2000 |
|
|
|
|
|
J. Sul, K. S. Panageas, A. B. Lassman, A. Hormigo, C. Nolan, I. T.
Gavrilovic, S. A. Grimm, L. M. DeAngelis, L. E. Abrey A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2031 |
|
|
|
|
|
* |
W. Taal, D. Brandsma, H. G. de Bruin, J. E. Bromberg, A. T.
Swaak-Kragten, W. M. Eijkenboom, M. J. van den Bent The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2009 |
|
|
|
|
M. J. Van Den Bent, A. Brandes, R. Rampling, M. Kouwenhoven, J. M. Kros,
A. F. Carpentier, P. Clement, B. Klughammer, T. Gorlia, D. Lacombe Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2005 |
|
|
** |
M. Vinjamuri, R. Adumala, R. Altaha, J. Hobbs, E. Crowell Retrospective analysis of glioblastoma multiforme (GBM) patients treated initially with BCNU compared to temozolomide (TMZ) with concomitant radiation therapy. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2071 |
|
|
|
|
* |
F. S. Viola, A. Katz, A. Arantes, A. Gaiger, C. Vasconcellos, V. Passos,
C. H. Barrios Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2056 |
|
Y. Wang, N. Makhani, M. Tsao Evaluation of clinical markup with CT simulation in whole brain radiation therapy. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2043 |
|
|
P. Y. Wen, V. Puduvalli, J. Kuhn, J. Reid, T. Cloughesy, W. A. Yung, S.
M. Chang, H. I. Robbins, R. McGovern, M. Ames, M. D. Prados
Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03). 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2039 |
|
|
** |
W. Wick, A. Wick, J. Schuth, M. Platten, G. Reifenberger, M. Weller One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma. 43rd ASCO Annual Meeting, June 1-5, 2007, McCormick Place, Chicago, Illinois, Abstract No. 2032 |
| 72L | |
